243 related articles for article (PubMed ID: 35288465)
21. Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer.
Yuan M; Zhai Y; Men Y; Zhao M; Sun X; Ma Z; Bao Y; Yang X; Sun S; Liu Y; Zhang W; Hui Z
Oxid Med Cell Longev; 2022; 2022():5479491. PubMed ID: 35154567
[TBL] [Abstract][Full Text] [Related]
22. High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors.
Lin L; Kane N; Kobayashi N; Kono EA; Yamashiro JM; Nickols NG; Reiter RE
Clin Cancer Res; 2021 Mar; 27(5):1505-1515. PubMed ID: 33219015
[TBL] [Abstract][Full Text] [Related]
23. Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model.
Wu L; Wu MO; De la Maza L; Yun Z; Yu J; Zhao Y; Cho J; de Perrot M
Oncotarget; 2015 May; 6(14):12468-80. PubMed ID: 25980578
[TBL] [Abstract][Full Text] [Related]
24. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
25. Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.
Revenko A; Carnevalli LS; Sinclair C; Johnson B; Peter A; Taylor M; Hettrick L; Chapman M; Klein S; Solanki A; Gattis D; Watt A; Hughes AM; Magiera L; Kar G; Ireland L; Mele DA; Sah V; Singh M; Walton J; Mairesse M; King M; Edbrooke M; Lyne P; Barry ST; Fawell S; Goldberg FW; MacLeod AR
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35387780
[TBL] [Abstract][Full Text] [Related]
26. Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.
Rodriguez-Ruiz ME; Rodriguez I; Garasa S; Barbes B; Solorzano JL; Perez-Gracia JL; Labiano S; Sanmamed MF; Azpilikueta A; Bolaños E; Sanchez-Paulete AR; Aznar MA; Rouzaut A; Schalper KA; Jure-Kunkel M; Melero I
Cancer Res; 2016 Oct; 76(20):5994-6005. PubMed ID: 27550452
[TBL] [Abstract][Full Text] [Related]
27. Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy.
Buchwald ZS; Nasti TH; Lee J; Eberhardt CS; Wieland A; Im SJ; Lawson D; Curran W; Ahmed R; Khan MK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028691
[TBL] [Abstract][Full Text] [Related]
28. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy.
Lauret Marie Joseph E; Kirilovsky A; Lecoester B; El Sissy C; Boullerot L; Rangan L; Marguier A; Tochet F; Dosset M; Boustani J; Ravel P; Boidot R; Spehner L; Haicheur-Adjouri N; Marliot F; Pallandre JR; Bonnefoy F; Scripcariu V; Van den Eynde M; Cornillot E; Mirjolet C; Pages F; Adotevi O
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230108
[TBL] [Abstract][Full Text] [Related]
29. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
[TBL] [Abstract][Full Text] [Related]
31. MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer.
Prasad M; Zorea J; Jagadeeshan S; Shnerb AB; Mathukkada S; Bouaoud J; Michon L; Novoplansky O; Badarni M; Cohen L; Yegodayev KM; Tzadok S; Rotblat B; Brezina L; Mock A; Karabajakian A; Fayette J; Cohen I; Cooks T; Allon I; Dimitstein O; Joshua B; Kong D; Voronov E; Scaltriti M; Carmi Y; Conde-Lopez C; Hess J; Kurth I; Morris LGT; Saintigny P; Elkabets M
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35292516
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of antitumor immune response by radiation therapy combined with dual immune checkpoint inhibitor in a metastatic model of HER2-positive murine tumor.
Misaki S; Murata S; Shimoji M; Iwai T; Sihombing AM; Aoki K; Takahashi Y; Watanabe Y
Jpn J Radiol; 2022 Dec; 40(12):1307-1315. PubMed ID: 35763240
[TBL] [Abstract][Full Text] [Related]
33. IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.
Johnson Z; Tarantelli C; Civanelli E; Cascione L; Spriano F; Fraser A; Shah P; Nomanbhoy T; Napoli S; Rinaldi A; Niewola-Staszkowska K; Lahn M; Perrin D; Wenes M; Migliorini D; Bertoni F; van der Veen L; Di Conza G
Cancer Res Commun; 2023 Apr; 3(4):576-591. PubMed ID: 37066023
[TBL] [Abstract][Full Text] [Related]
34. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
35. BR101801 enhances the radiosensitivity of p53-deficient colorectal cancer cells by inducing G2/M arrest, apoptosis, and senescence in a p53-independent manner.
Park M; Ha J; Lee Y; Kwon Y; Choi SH; Kim BS; Jeong YK
Am J Cancer Res; 2023; 13(12):5887-5900. PubMed ID: 38187039
[TBL] [Abstract][Full Text] [Related]
36. Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
Groeneveldt C; Kinderman P; van den Wollenberg DJM; van den Oever RL; Middelburg J; Mustafa DAM; Hoeben RC; van der Burg SH; van Hall T; van Montfoort N
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082167
[TBL] [Abstract][Full Text] [Related]
37. PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8
Carnevalli LS; Sinclair C; Taylor MA; Gutierrez PM; Langdon S; Coenen-Stass AML; Mooney L; Hughes A; Jarvis L; Staniszewska A; Crafter C; Sidders B; Hardaker E; Hudson K; Barry ST
J Immunother Cancer; 2018 Dec; 6(1):158. PubMed ID: 30587236
[TBL] [Abstract][Full Text] [Related]
38. PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.
Hanna BS; Roessner PM; Scheffold A; Jebaraj BMC; Demerdash Y; Öztürk S; Lichter P; Stilgenbauer S; Seiffert M
Leukemia; 2019 Jun; 33(6):1427-1438. PubMed ID: 30573773
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy Targeting CCR8+ Regulatory T Cells Induces Antitumor Effects via Dramatic Changes to the Intratumor CD8+ T Cell Profile.
Ueyama A; Nogami W; Nashiki K; Haruna M; Miwa H; Hagiwara M; Nagira M; Wada H; Nagira Y
J Immunol; 2023 Aug; 211(4):673-682. PubMed ID: 37350632
[TBL] [Abstract][Full Text] [Related]
40. Nanoscale Reduced Graphene Oxide-Mediated Photothermal Therapy Together with IDO Inhibition and PD-L1 Blockade Synergistically Promote Antitumor Immunity.
Yan M; Liu Y; Zhu X; Wang X; Liu L; Sun H; Wang C; Kong D; Ma G
ACS Appl Mater Interfaces; 2019 Jan; 11(2):1876-1885. PubMed ID: 30582788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]